2 Dividend Stocks to Buy and Hold For 10 Years
These drugmakers can perform well despite competition and patent cliffs facing them. Both have excellent dividend programs and have increased their payouts at a good clip.
BMY - Bristol-Myers Squibb Company
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$55.50
DETAILS
HIGH:
$65.00
LOW:
$37.00
MEDIAN:
$60.00
CONSENSUS:
$55.50
UPSIDE:
0.43%
Stock News
2 Buffett Stocks to Load Up On—And 1 to Ditch
Warren Buffett made some substantial changes to the Berkshire Hathaway Inc. NYSE: BRK.B portfolio in the first quarters of 2025, including selling off some $4 billion in Apple Inc. NASDAQ: AAPL...
Bristol Myers Squibb Company (NYSE:BMY) Given Average Recommendation of “Hold” by Brokerages
Shares of Bristol Myers Squibb Company (NYSE: BMY - Get Free Report) have been given a consensus recommendation of "Hold" by the twenty-one analysts that are currently covering the stock,...
Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $55.26, indicating a -2.4% shift from the previous trading day.
Bristol Myers Squibb Company $BMY Shares Purchased by Fjarde AP Fonden Fourth Swedish National Pension Fund
Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 7.8% in the third quarter, according to the company in its most...
Conning Inc. Reduces Position in Bristol Myers Squibb Company $BMY
Conning Inc. decreased its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 2.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned...
Analyzing Bristol Myers Squibb (NYSE:BMY) & VivoSim Labs (NASDAQ:VIVS)
VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two...
Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?
BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus Shares Jump After Strong Preliminary 2025 Results
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM.
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
Market Today: Meta taps nuclear; GM books $6B EV charge
Stock News California billionaire tax splits tech leaders: Nvidia (NVDA) CEO Jensen Huang said he's âfineâ with a proposed one-time 5% California wealth tax
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 17.3% over the past six months compared with the industry's growth of 23.4%.
Cerity Partners LLC Has $42.50 Million Holdings in Bristol Myers Squibb Company $BMY
Cerity Partners LLC grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 9.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission....
CX Institutional Has $7.48 Million Stock Position in Bristol Myers Squibb Company $BMY
CX Institutional grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 9.2% during the undefined quarter, according to the company in its most recent filing with the Securities and...
3 Drug Stocks to Buy at a Discount
Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Price Targets
Bristol Myers price target raised to $60 from $54 at Leerink
$60.00
(was $56.39)
David Risinger
·
Leerink Partners
Bristol Myers price target raised to $60 from $53 at Scotiabank
$60.00
(was $55.87)
Louise Chen
·
Scotiabank
Bristol Myers upgraded to Buy from Neutral at UBS
$65.00
(was $56.41)
UBS
Bristol Myers price target raised to $37 from $36 at Morgan Stanley
$37.00
(was $52.63)
Morgan Stanley
Bristol Myers upgraded to Buy from Neutral at Guggenheim
$62.00
(was $51.20)
Guggenheim
Bristol Myers price target raised to $53 from $50 at HSBC
$53.00
(was $50.68)
HSBC
Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at Scotiabank
$53.00
(was $50.96)
Louis Chen
·
Scotiabank
Truist Securities on Bristol-Myers Squibb Co. (BMY): 'overall positive'
$65.00
(was $50.98)
Srikripa Devarakonda
·
Truist Financial
Bristol Myers downgraded to Neutral from Outperform at Daiwa
$42.00
(was $45.85)
Narumi Nakagiri
·
Daiwa
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
$84.00
(was $47.12)
David Macdonald
·
Truist Financial
Bristol Myers price target lowered to $68 from $70 at Jefferies
$68.00
(was $48.52)
Akash Tewari
·
Jefferies
Piper Sandler bullish on Bristol Myers, initiates with an Overweight
$65.00
(was $49.82)
David Amsellem
·
Piper Sandler
Bristol Myers price target raised to $61 from $57 at BMO Capital
$61.00
(was $56.23)
Evan Seigerman
·
BMO Capital
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital
$57.00
(was $54.32)
Evan David Seigerman
·
BMO Capital
BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
$48.00
(was $49.56)
Evan David Seigerman
·
BMO Capital
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs
$57.00
(was $50.55)
Chris Shibutani
·
Goldman Sachs
Bristol Myers downgraded to Underweight from Equal Weight at Barclays
$41.00
(was $50.45)
Carter Gould
·
Barclays
Bristol Myers price target lowered to $43 from $47 at UBS
$43.00
(was $40.68)
Trung Huynh
·
UBS
TD Cowen Reiterates Hold Rating on Bristol-Myers Squibb Co. (BMY)
$67.00
(was $44.11)
Steve Scala
·
Cowen & Co.
Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?
$55.00
(was $49.87)
James Shin
·
Deutsche Bank